Büchi Labortechnik

7th Annual Protein Kinases Congress, Berlin, Germany

Monday, March 10, 2008 - Wednesday, March 12, 2008

Print Email to a friend

Innovating kinase inhibitor development is the key to successful clinical development. At Informa Life Sciences 7th Annual Protein Kinases Congress hear the latest thinking and strategies towards creating a selective inhibitor. Learn about new targets, industry trends in structure-based drug design, clinical case-studies and discuss the issue of cardiotoxicity.

Topics to be discussed include:


  • Target identification and validation of GSK-3

  • Non-ATP binding

  • Prediciting off-target toxicity

  • Selectivity assessment

  • Systems biology and phosphoproteomics

  • Challenges and success stories in early clinical trials:


    • Biomarkers for efficacy

    • Dasatinib

    • XL-880/XL-184

    • MLN8054

    • AZD1152

    • PKC-Lambda

  • Therapeutic areas include:


    • Inflammation

    • Neurology

    • Oncology

    • Transplantation

At Europe's leading industry protein kinase meeting discuss the hottest topics that directly impact the success of your discovery and development programme. Benchmark your ideas against others and take new strategies back to the workplace. What can you do in discovery to help those in development?

Further Information: http://www.iir-events.com/IIR-Conf/page.aspx?id=9551